Genetic approaches designed to minimize cytotoxicity of retroviral protease.
Virus Laboratory, DuPont Merck Company, Glenolden, Pennsylvania 19036.
C J
CJ
Rizzo
B D
BD
Korant
D000595:Amino Acid Sequence; D001407:Bacillus / Q000235:genetics; D001692:Biological Transport; D003001:Cloning, Molecular / Q000379:methods*; D003588:Cytopathogenic Effect, Viral; D004926:Escherichia coli; D015964:Gene Expression Regulation, Bacterial; D015971:Gene Expression Regulation, Enzymologic; D005813:Genes, Synthetic; D005822:Genetic Vectors; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology* / Q000235:genetics / Q000502:physiology; D008969:Molecular Sequence Data; D011401:Promoter Regions, Genetic; D011499:Protein Processing, Post-Translational; D011993:Recombinant Fusion Proteins / Q000378:metabolism*; D012995:Solubility; D013604:T-Phages / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
D011993:Recombinant Fusion Proteins; D016333:HIV Protease; D001618:beta-Lactamases